Anna Maria Fink

Mutations driving CLL and their evolution in progression and relapse

Dan A. Landau, Eugen Tausch, Amaro Taylor‐Weiner et al. · Nature · 2015 · 1K citations · Full text

Genome Instability, Somatic Variant, Genetic Disorder +6

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

Kirsten Fischer, Jasmin Bahlo, Anna Maria Fink et al. · Blood · 2015 · 693 citations · Full text

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial

Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka et al. · Blood · 2014 · 502 citations

Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial

Sebastian Böttcher, Matthias Ritgen, Kirsten Fischer et al. · Journal of Clinical Oncology · 2012 · 445 citations

Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group

Gábor Kovács, Sandra Robrecht, Anna Maria Fink et al. · Journal of Clinical Oncology · 2016 · 170 citations